UPDATE – PharmaEssentia has corrected the press release issued 6 January about the Phase III results for Besremi in essential thrombocytopenia to note the incidence of two treatment-related serious adverse events in the Besremi arm; the previous press release reported zero TRSAEs. Scrip has revised this article to include the new data and confirmed the company’s view that Besremi has a relatively better safety profile than anagrelide.
With Phase III Success, PharmaEssentia To Seek Besremi Label Expansion (Update)
Taiwan-based PharmaEssentia hopes to add essential thrombocytopenia to the label for its pegylated interferon product, already approved to treat polycythemia vera.
More from Clinical Trials
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.